ID   G-401
AC   CVCL_0270
SY   G401; G 401
DR   BTO; BTO:0002586
DR   CLO; CLO_0003434
DR   EFO; EFO_0002179
DR   MCCL; MCC:0000161
DR   CLDB; cl1409
DR   4DN; 4DNSR6XERO32
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1441
DR   BioSample; SAMN03470969
DR   BioSample; SAMN03472819
DR   BioSample; SAMN10987919
DR   cancercelllines; CVCL_0270
DR   CCRID; 1101HUM-PUMC000034
DR   Cell_Model_Passport; SIDM00856
DR   ChEMBL-Cells; CHEMBL3308394
DR   ChEMBL-Targets; CHEMBL613509
DR   Cosmic; 683682
DR   Cosmic; 802044
DR   Cosmic; 802245
DR   Cosmic; 907299
DR   Cosmic-CLP; 907299
DR   DepMap; ACH-000096
DR   ECACC; 87042204
DR   EGA; EGAS00001000978
DR   ENCODE; ENCBS062JBT
DR   ENCODE; ENCBS432GBV
DR   ENCODE; ENCBS629BMK
DR   ENCODE; ENCBS659PBH
DR   GDSC; 907299
DR   GEO; GSM827165
DR   GEO; GSM887017
DR   GEO; GSM888086
DR   GEO; GSM1669799
DR   GEO; GSM1676299
DR   GEO; GSM1701634
DR   GEO; GSM2033123
DR   GEO; GSM2033124
DR   GEO; GSM2033125
DR   GEO; GSM2033126
DR   GEO; GSM2033127
DR   GEO; GSM2033128
DR   GEO; GSM2409659
DR   GEO; GSM2409660
DR   GEO; GSM2409661
DR   GEO; GSM2409662
DR   GEO; GSM2409663
DR   GEO; GSM2495985
DR   GEO; GSM2787352
DR   IARC_TP53; 21334
DR   IGRhCellID; G401
DR   JCRB; JCRB9065
DR   LiGeA; CCLE_546
DR   LINCS_LDP; LCL-1511
DR   PharmacoDB; G401_374_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0270
DR   PubChem_Cell_line; CVCL_0270
DR   TOKU-E; 1303
DR   Wikidata; Q54835347
RX   PubMed=8382007;
RX   PubMed=9671307;
RX   PubMed=10397258;
RX   PubMed=10602515;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=25877200;
RX   PubMed=26351324;
RX   PubMed=27397505;
RX   PubMed=28945250;
RX   PubMed=30894373;
RX   PubMed=30924592;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/g/cell-lines-detail-286.html
CC   Problematic cell line: Misclassified. Originally thought to be a Wilms tumor cell line but is a kidney rhabdoid tumor cell line (PubMed=8382007; PubMed=30924592).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Homozygous (PubMed=9671307; PubMed=10602515; PubMed=28945250).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: H3K27me3 ChIP-seq epigenome analysis.
CC   Omics: H3K4me3 ChIP-seq epigenome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=2.48%; Native American=0.75%; East Asian, North=2.12%; East Asian, South=0.55%; South Asian=8.63%; European, North=29.24%; European, South=56.23% (PubMed=30894373).
CC   Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
ST   Source(s): ATCC; CCRID; Cosmic-CLP; ECACC; JCRB; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 11,13
ST   D13S317: 9,14
ST   D16S539: 12
ST   D18S51: 14
ST   D19S433: 13,14
ST   D21S11: 31,32.2 (CCRID)
ST   D21S11: 31,32.2,33.2 (PubMed=25877200)
ST   D2S1338: 18,24
ST   D3S1358: 16,18
ST   D5S818: 13
ST   D7S820: 11,14
ST   D8S1179: 13,14
ST   FGA: 24,27
ST   Penta D: 10,11
ST   Penta E: 7
ST   TH01: 8,9.3 (ATCC; CCRID; Cosmic-CLP; ECACC; JCRB)
ST   TH01: 9.3 (PubMed=25877200)
ST   TPOX: 8,11 (ATCC; CCRID; Cosmic-CLP; ECACC; JCRB)
ST   TPOX: 11 (PubMed=25877200)
ST   vWA: 16
DI   NCIt; C8715; Rhabdoid tumor of the kidney
DI   ORDO; Orphanet_69077; Rhabdoid tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   3M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 41
//
RX   PubMed=8382007;
RA   Garvin A.J., Re G.G., Tarnowski B.I., Hazen-Martin D.J., Sens D.A.;
RT   "The G401 cell line, utilized for studies of chromosomal changes in
RT   Wilms' tumor, is derived from a rhabdoid tumor of the kidney.";
RL   Am. J. Pathol. 142:375-380(1993).
//
RX   PubMed=9671307; DOI=10.1038/28212;
RA   Versteege I., Sevenet N., Lange J., Rousseau-Merck M.-F., Ambros P.F.,
RA   Handgretinger R., Aurias A., Delattre O.;
RT   "Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer.";
RL   Nature 394:203-206(1998).
//
RX   PubMed=10397258;
RA   Rousseau-Merck M.-F., Versteege I., Legrand I., Couturier J.,
RA   Mairal A., Delattre O., Aurias A.;
RT   "hSNF5/INI1 inactivation is mainly associated with homozygous
RT   deletions and mitotic recombinations in rhabdoid tumors.";
RL   Cancer Res. 59:3152-3156(1999).
//
RX   PubMed=10602515; DOI=10.1038/sj.onc.1203168;
RA   DeCristofaro M.F., Betz B.L., Wang W.-D., Weissman B.E.;
RT   "Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and
RT   primary rhabdomyosarcomas but not Wilms' tumors.";
RL   Oncogene 18:7559-7565(1999).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28945250; DOI=10.1038/ng.3958;
RA   Nakayama R.T., Pulice J.L., Valencia A.M., McBride M.J.,
RA   McKenzie Z.M., Gillespie M.A., Ku W.L., Teng M.-X., Cui K.-R.,
RA   Williams R.T., Cassel S.H., Qing H., Widmer C.J., Demetri G.D.,
RA   Irizarry R.A., Zhao K.-J., Ranish J.A., Kadoch C.;
RT   "SMARCB1 is required for widespread BAF complex-mediated activation of
RT   enhancers and bivalent promoters.";
RL   Nat. Genet. 49:1613-1623(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30924592; DOI=10.1002/pbc.27741;
RA   Pritchard-Jones K., Perotti D.;
RT   "WARNING: G-401 and SK-NEP-1 cell lines are not Wilms tumor cell
RT   lines.";
RL   Pediatr. Blood Cancer 66:e27741.1-e27741.2(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//